Anifrolumab (Saphnelo) listed in NS

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles:

Grief and Lupus: The Forgotten Symptom of Chronic Illness

Read

Lupus and Heart Health: Understanding Cardiovascular Risk in SLE

Read

OCT Screening Hydroxychloroquine Coverage | Lupus Canada Advocacy

Read